-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sabirnetug in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sabirnetug in Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sabirnetug in Alzheimer's Disease Drug Details: ACU-193 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sabirnetug in Mild Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sabirnetug in Mild Cognitive Impairment report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sabirnetug in Mild Cognitive Impairment Drug Details: ACU-193 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sabirnetug in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sabirnetug in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sabirnetug in Dementia Associated With Alzheimer's Disease Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MHB-088C in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MHB-088C in Metastatic Colorectal Cancer Drug Details: MHB-088C is under...
-
Product Insights
NewNet Present Value Model: Acumen Pharmaceuticals Inc’s ACU-193
Empower your strategies with our Net Present Value Model: Acumen Pharmaceuticals Inc's ACU-193 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)...
-
Product Insights
NewMild Cognitive Impairment – Drugs In Development, 2024
Empower your strategies with our Mild Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety, and apathy. Risk factors include diabetes, high blood pressure, depression, smoking, and elevated cholesterol. The Mild...
-
Product Insights
NewDementia Associated With Alzheimer’s Disease – Drugs In Development, 2024
Empower your strategies with our Dementia Associated With Alzheimer's Disease – Drugs In Development, 2024 report and make more profitable business decisions. Alzheimer's disease (AD) is the most common cause of dementia. AD is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and changes in behavior and thinking skills that interfere with daily functioning. Early symptoms may include mild forgetfulness, difficulty recalling recent events or information, and trouble with problem-solving or complex tasks. One of the hallmark features of...
-
Product Insights
NewCognitive Impairment – Drugs In Development, 2024
Empower your strategies with our Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Cognitive impairment is a condition characterized by a decline in cognitive functions, such as memory, attention, and problem-solving skills. It can range from mild to severe and may result from various causes, including aging, neurodegenerative diseases (like Alzheimer's), vascular disorders, traumatic brain injuries, infections, medication side effects, mental health issues, nutritional deficiencies, or environmental factors. Symptoms can include memory loss, confusion, difficulty...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACU-193 in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACU-193 in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACU-193 in Dementia Associated With Alzheimer's Disease Drug Details:...